Viking’s stock plummets on obesity pill trial results
Viking Therapeutics’ dual-targeting oral weight loss drug has disappointed investors after it showed lower efficacy than offerings from pharma giants…
News
Trade-offs abound as big pharma makes direct-to-consumer transition
CSL slashes 15% of workforce and offshoots vaccine division
Santen and RemeGen sign licence deal for retinal disease injection
Merck announces EC approval of Ogsiveo for desmoid tumours
Boehringer Ingelheim marks retinal disease push with $327m licensing deal
FDA approves Papzimeos as first therapy for HPV-caused airway disease
Wegovy becomes first GLP-1RA to gain FDA MASH approval
